research This Month in JAAD: October 2021
Oral baricitinib is effective and safe for treating alopecia areata.
Search
for
Sort by
Research
900-930 / 1000+ resultsresearch 098 Simvastatin decreases AA-associated inflammation through effects on isoprenoid metabolites
Simvastatin reduces inflammation and promotes hair regrowth in alopecia areata.
research THERAPEUTIC EVALUATION OF ḤIJAMAH BIL SHART IN QILLAT SH'AR (ANDROGENETIC ALOPECIA): A CASE STUDY WITH UNANI AND BIOMEDICAL INSIGHTS
Wet cupping may improve hair health in androgenetic alopecia without side effects.
research Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review
Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
research Minoxidil/salicylic acid hydrogel formulated for alopecia treatment: Supramolecular interactions modulate physicochemical properties and biological activities revealed by experimental and theoretical studies
The new minoxidil and salicylic acid hydrogel improves alopecia treatment.
research 708 SIG-1451: A topical anti-inflammatory new chemical entity for atopic dermatitis (AD)
SIG-1451 could be a promising new treatment for atopic dermatitis.
research Gingival Hyperplasia Secondary to Everolimus Therapy
A woman developed thick gums from everolimus treatment after a kidney transplant.
research Rational Design and Synthesis of 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
research Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response
Baricitinib effectively regrows hair in severe alopecia areata cases.
research ISID1116 – Novel androgen receptor degrader for androgenetic alopecia (AGA) application
research Use of intramuscular triamcinolone acetonide in intermediate responders to janus kinase inhibition for alopecia areata: Case report
IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.
research Analyzing the role of tofacitinib in treatment of alopecia areata: A retrospective analysis from a tertiary care center of North India
Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
research Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus
Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
research Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study
The inhibitor affects androgen metabolism but not ovarian function.
research Lareb provides update on lamotrigine-associated alopecia
Lamotrigine can cause hair loss in some patients.
research The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research Vitamin E TPGS based transferosomes augmented TAT as a promising delivery system for improved transdermal delivery of raloxifene
The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research PERICARDIAL EFFUSIONS ASSOCIATED WITH MINOXIDIL
research Topiramate-induced hair loss in a patient using valproate and levetiracetam
research Volume 1982, No. 4 February 26, 1982
Some medications caused temporary health issues that improved after stopping the drugs, but two patients died from liver problems linked to carbamazepine.
research Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review
A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.
research The Role of Tofacitinib in the Management of Alopecia Totalis
Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
research Development and characterization of polymeric nanoparticle-based formulation of adapalene for topical acne therapy
The new adapalene formulation using TyroSpheres is more effective and less irritating for acne treatment.
research Methotrexate
A woman developed skin irritation from treatments for hair loss, showing allergies to both minoxidil and saw palmetto solutions.
research Tanshinone IIA pretreatment protects free flaps against hypoxic injury by upregulating stem cell-related biomarkers in epithelial skin cells
Tanshinone IIA helps protect skin tissue from low oxygen damage by boosting certain cell markers.
research Comparative Analysis of Clinical Outcomes in Patients With Type 2 Diabetes Mellitus on Monotherapy Versus Combination Therapy
Combination therapy is better for long-term control and outcomes in type 2 diabetes.